🇺🇸 FDA
Patent

US 9062310

Compositions and methods for inhibiting expression of factor VII gene

granted A61PA61P29/00A61P31/12

Quick answer

US patent 9062310 (Compositions and methods for inhibiting expression of factor VII gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P29/00, A61P31/12, A61P43/00, A61P7/04